A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial

• Published in: The Lancet (British edition) Vol. 371; no. 9616; pp. 899 - 907
• Main Authors: Ormiston, John A, MB, Serruys, Patrick W, Prof, Regar, Evelyn, MD, Dudek, Dariusz, MD, Thuesen, Leif, MD, Webster, Mark WI, MB, Onuma, Yoshinobu, MD, Garcia-Garcia, Hector M, MD, McGreevy, Robert, PhD, Veldhof, Susan, RN
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 15.03.2008; Elsevier Limited
• Subjects: Absorbable Implants; Angioplasty; Angioplasty, Balloon, Coronary; Clinical trials; Coronary Disease - diagnostic imaging; Coronary Disease - therapy; Coronary Restenosis; Coronary vessels; Drug-Eluting Stents; Everolimus; Female; Heart attacks; Humans; Immunosuppressive Agents; Internal Medicine; Lesions; Male; Middle Aged; Myocardial infarction; Prospective Studies; Safety; Sirolimus - analogs & derivatives; Stents; Thromboembolism; Ultrasonography

Summary Background A fully bioabsorbable drug-eluting coronary stent that scaffolds the vessel wall when needed and then disappears once the acute recoil and constrictive remodelling processes have subsided has theoretical advantages. The bioasorbable everolimus-eluting stent (BVS) has a backbone of...